PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2012-11-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00793546
- Locations
Pfizer Investigational Site
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
- Conditions
- Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00793871
- Locations
- 🇨🇳
Nanjing Bayi Hospital, Nanjing, Jiangsu, China
🇨🇳Cancer Institute & Hospital Chinese Academy of Medical Sciences and PUMC, Bejing, China
🇨🇳Beijing Cancer Hospital, Beijing, China
Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT00793000
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT00791492
- Locations
- 🇵🇹
Unidade Clinica de Paramiloidose-Hospital Santo Antonio, Porto, Portugal
🇦🇷FLENI-Hepatology and Organ Transplant Dept., Ciudad de Buenos Aires, Argentina
🇸🇪Umea University Hospital, Umea, Sweden
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
- Conditions
- Huntington DiseaseAlzheimer Disease
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00788047
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
- Conditions
- Healthy Volunteers
- Interventions
- Biological: tanezumab
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT00788294
- Locations
- 🇺🇸
Pfizer Investigational Site, Cypress, California, United States
Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
- Conditions
- Age-related Macular Degeneration
- Interventions
- Other: no intervention
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 108
- Registration Number
- NCT00787319
- Locations
- 🇨🇿
Pfizer Investigational Site, Usti nad Labem, Czechia
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 222
- Registration Number
- NCT00787150
- Locations
- 🇯🇵
Pfizer Investigational Site, Kumamoto, Japan
A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: CP- 690 550Other: placebo
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2013-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 195
- Registration Number
- NCT00787202
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Phase1, Single Dose, Crossover Study to Determine Bioequivalence
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2010-09-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00786240
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore